Indian govt study exhorts companies to navigate and capitalize on patent cliff
As over 20 drugs with a combined annual sales value of $250 billion are set to go off-patent, Indian companies have been exhorted to step in with generic and biosimilar versions.
Noting that a massive market opportunity awaits generic drug manufacturers, the Indian government is encouraging domestic pharma majors to seize the opportunity in a global market seeking economical solutions by manufacturing affordable alternatives, reports The Pharma Letter’s India correspondent.
A study for the Department of Pharmaceuticals study has revealed that by 2030, patents for 24 major blockbuster drugs, including global top-sellers like Humira (adalimumab), Keytruda (pembrolizumab), Opdivo (nivolumab), Ibrance (palbociclib) and Symbicort (budesonide) will expire, unleashing a market valued at over $250 billion.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biosimilars
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze